Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock traders acquired 4,063 put options on the stock. This represents an increase of 2,362% compared to the average volume of 165 put options.
Wall Street Analyst Weigh In
XENE has been the topic of several research reports. Royal Bank of Canada reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. Deutsche Bank Aktiengesellschaft started coverage on Xenon Pharmaceuticals in a report on Tuesday, February 11th. They issued a "buy" rating and a $67.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $53.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Finally, William Blair restated an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Xenon Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $57.38.
View Our Latest Stock Analysis on XENE
Xenon Pharmaceuticals Stock Performance
Shares of NASDAQ:XENE traded up $0.49 during mid-day trading on Friday, hitting $35.34. 475,319 shares of the company traded hands, compared to its average volume of 378,967. The firm's 50 day simple moving average is $38.14 and its 200 day simple moving average is $39.88. The firm has a market cap of $2.71 billion, a P/E ratio of -12.53 and a beta of 1.26. Xenon Pharmaceuticals has a 52-week low of $33.27 and a 52-week high of $46.00.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.05. Equities research analysts expect that Xenon Pharmaceuticals will post -3.1 EPS for the current fiscal year.
Insider Buying and Selling
In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 16,315 shares of the stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $40.50, for a total transaction of $660,757.50. Following the transaction, the chief executive officer now owns 31,302 shares of the company's stock, valued at $1,267,731. This trade represents a 34.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 5.52% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Xenon Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth about $63,000. Quarry LP purchased a new position in shares of Xenon Pharmaceuticals during the 4th quarter valued at approximately $78,000. Blue Trust Inc. grew its position in shares of Xenon Pharmaceuticals by 140.3% during the fourth quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock worth $95,000 after buying an additional 1,414 shares in the last quarter. Avior Wealth Management LLC bought a new stake in shares of Xenon Pharmaceuticals in the fourth quarter worth $101,000. Finally, KBC Group NV raised its holdings in Xenon Pharmaceuticals by 39.8% in the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock valued at $107,000 after acquiring an additional 780 shares in the last quarter. Institutional investors and hedge funds own 95.45% of the company's stock.
About Xenon Pharmaceuticals
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Read More
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
